Dren Bio Announces Strategic Collaboration With Novartis To Develop Novel Targeted Myeloid Engagers For Cancer; Dren Bio To Receive Total Upfront Consideration Of $150M And Is Eligible To Receive Milestone Payments And Tiered Royalties
Dren Bio Announces Strategic Collaboration With Novartis To Develop Novel Targeted Myeloid Engagers For Cancer; Dren Bio To Receive Total Upfront Consideration Of $150M And Is Eligible To Receive Milestone Payments And Tiered Royalties
– Collaboration combines Dren's targeted cell depletion platform with Novartis research, development and commercial expertise to advance innovative therapies for cancer –
合作将Dren的靶向电芯耗尽平台与诺华的研发和商业专业知识结合起来，推进癌症创新疗法的开发。
– Dren Bio to receive total upfront consideration of $150 million and is eligible to receive milestone payments and tiered royalties –
Dren Bio将获得总前段补偿$15000万，并有资格获得里程碑付款和阶梯式版税。
Dren Bio, Inc. ("Dren Bio" or the "Company"), a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune, and other serious diseases, today announced that it has entered into a strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE:NVS). The collaboration will focus on the discovery and development of therapeutic bispecific antibodies for cancer using Dren Bio's proprietary Targeted Myeloid Engager and Phagocytosis Platform.
Dren Bio，Inc.（“Dren Bio”或“公司”）是一家私营的临床阶段生物制品公司，致力于开发抗体治疗癌症、自身免疫和其他严重疾病。今天宣布与诺华制药有限公司（诺华制药 AG的子公司（NYSE：NVS））签订了战略合作协议。合作将侧重于使用Dren Bio的专有目标髓系结合和吞噬平台，发现和开发癌症的治疗性双特异性抗体。
